A Versatile Orthotopic Nude Mouse Model for Study of Esophageal Squamous Cell Carcinoma

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Ip, Joseph Chok Yan ^a   Ko, Josephine Mun Yee ^a   Yu, Valen Zhuoyou ^a   Chan, Kwok Wah ^a,b   Lam, Alfred K ^a   Law, Simon ^a,b   Tong, Daniel King Hung ^a   Lung, Maria Li ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b GRIFFITH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

LUCIFERASE; PROTEIN KINASE B; SHORT HAIRPIN RNA; ONCOPROTEIN; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; CANCER CELL LINE; CELL INTERACTION; CELL LABELING; CONTROLLED STUDY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GENE FUNCTION; HISTOPATHOLOGY; LYMPH VESSEL METASTASIS; MOUSE; NONHUMAN; PERINEURAL INVASION; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR GROWTH; TUMOR INVASION; TUMOR MICROENVIRONMENT; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOGENESIS; CELL PROLIFERATION; DISEASE MODEL; ESOPHAGUS TUMOR; GENETICS; HUMAN; METABOLISM; NUDE MOUSE; PATHOLOGY; SQUAMOUS CELL CARCINOMA;

ANIMALIA; MUS MUSCULUS;

ANIMALS; CARCINOGENESIS; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; ESOPHAGEAL NEOPLASMS; HUMANS; MICE; MICE, NUDE; ONCOGENE PROTEIN V-AKT; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STROMAL CELLS; TUMOR MICROENVIRONMENT;

EID: 84925308648     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/910715     Document Type: Article

References (50)

1. P. C. Enzinger and R. J. Mayer, "Esophageal cancer," The New England Journal of Medicine, vol. 349, no. 23, pp. 2241-2252, 2003.
2. A. Pennathur, M. K. Gibson, B. A. Jobe, and J. D. Luketich, "Oesophageal carcinoma," The Lancet, vol. 381, no. 9864, pp. 400-412, 2013.
3. J. Ferlay, H. R. Shin, F. Bray, D. Forman, C. Mathers, and D. M. Parkin, "Estimates of worldwide burden of cancer in 2008: GLOBOCAN2008," International Journal of Cancer, vol. 127, no. 12, pp. 2893-2917, 2010.
4. R. Siegel, D. Naishadham, and A. Jemal, "Cancer statistics, 2013," CA: Cancer Journal for Clinicians, vol. 63, no. 1, pp. 11-30, 2013.
5. A. P. Vizcaino, V. Moreno, R. Lambert, and D. M. Parkin, "Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995," International Journal of Cancer, vol. 99, no. 6, pp. 860-868, 2002.
6. K. Y. Lam, L. T. Ma, and J. Wong, "Measurement of extent of spread of oesophageal squamous carcinoma by serial sectioning," Journal of Clinical Pathology, vol. 49, no. 2, pp. 124-129, 1996.
7. G. D. Stoner and A. Gupta, "Etiology and chemoprevention of esophageal squamous cell carcinoma," Carcinogenesis, vol. 22, no. 11, pp. 1737-1746, 2001.
8. S. Liu, J. Y. Dai, L. Yao et al., "Esophageal adenocarcinoma and its rare association with barrett's esophagus in Henan, China," PLoS ONE, vol. 9, no. 10, Article IDe110348, 2014.
9. C. Lepage, B. Rachet, V. Jooste, J. Faivre, and M. P. Coleman, "Continuing rapid increase in esophageal adenocarcinoma in England and Wales," The American Journal of Gastroenterology, vol. 103, no. 11, pp. 2694-2699, 2008.
10. A. P. Thrift and D. C. Whiteman, "The incidence of esophageal adenocarcinoma continues to rise: analysis of period and birth cohort effects on recent trends," Annals of Oncology, vol. 23, no. 12, Article IDmds181, pp. 3155-3162, 2012.
11. F. Kamangar, G. M. Dores, and W. F. Anderson, "Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world," Journal of Clinical Oncology, vol. 24, no. 14, pp. 2137-2150, 2006.
12. Z. Guohong, S. Min, W. DuenMei et al., "Genetic heterogeneity of oesophageal cancer in high-incidence areas of Southern and Northern China," PLoS ONE, vol. 5, no. 3, Article ID e9668, 2010.
13. D. Hanahan and R. A. Weinberg, "Hallmarks of cancer: the next generation," Cell, vol. 144, no. 5, pp. 646-674, 2011.
14. D. Hanahan and R. A. Weinberg, "Thehallmarks of cancer," Cell, vol. 100, no. 1, pp. 57-70, 2000.
15. D. E. Ingber, "Cancer as a disease of epithelial-mesenchymal interactions and extracellular matrix regulation," Differentiation, vol. 70, no. 9-10, pp. 547-560, 2002.
16. I. J. Fidler, C. Wilmanns, A. Staroselsky, R. Radinsky, Z. Dong, and D. Fan, "Modulation of tumor cell response to chemotherapy by the organ environment," Cancer and Metastasis Reviews, vol. 13, no. 2, pp. 209-222, 1994.
17. M. C. Bibby, "Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages," European Journal of Cancer, vol. 40, no. 6, pp. 852-857, 2004.
18. A. Richmond and S. Yingjun, "Mouse xenograftmodels vsGEM models for human cancer therapeutics," Disease Models and Mechanisms, vol. 1, no. 2-3, pp. 78-82, 2008.
19. J. J. Killion, R. Radinsky, and I. J. Fidler, "Orthotopicmodels are necessary to predict therapy of transplantable tumors in mice," Cancer and Metastasis Reviews, vol. 17, no. 3, pp. 279-284, 1998.
20. M. C. Bibby, "Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages," European Journal of Cancer, vol. 40, no. 6, pp. 852-857, 2004.
21. R. M. Hoffman, "Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic," Investigational New Drugs, vol. 17, no. 4, pp. 343-360, 1999.
22. R. S. Kerbel, "What is the optimal rodent model for anti-tumor drug testing?" Cancer and Metastasis Reviews, vol. 17, no. 3, pp. 301-304, 1998.
23. R. S. Kerbel, "Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved," Cancer Biology & Therapy, vol. 2, pp. 133-138, 2003.
24. T. Furihata, T. Sakai, H. Kawamata et al., "A new in vivo model for studying invasion and metastasis of esophageal squamous cell carcinoma," International journal of oncology, vol. 19, no. 5, pp. 903-907, 2001.
25. T. Hori, Y. Yamashita, M. Ohira, Y. Matsumura, K. Muguruma, and K. Hirakawa, "Novel orthotopic implantation model of human esophageal carcinoma in nude rats: CD44H mediates cancer cell invasion in vitro and in vivo," International Journal of Cancer, vol. 92, no. 4, pp. 489-496, 2001.
26. T. Ohara, M. Takaoka, K. Sakurama et al., "The establishment of a newmousemodel with orthotopic esophageal cancer showing the esophageal stricture," Cancer Letters, vol. 293, no. 2, pp. 207-212, 2010.
27. J. M. Daly, W. A. Fry, A. G. Little et al., "Esophageal cancer: results of American College of Surgeons Patient care Evaluation Study," Journal of the American College of Surgeons, vol. 190, no. 5, pp. 562-573, 2000.
28. C. S. Yang, "Research on esophageal cancer in China: a review," Cancer Research, vol. 40, 8, part 1, pp. 2633-2644, 1980.
29. C. P. Hu, H. G. Hsieh, K. Y. Chien et al., "Biologic properties of three newly established human esophageal carcinoma cell lines," Journal of the National Cancer Institute, vol. 72, no. 3, pp. 577-583, 1984.
30. Y. Shimada, M. Imamura, T. Wagata, N. Yamaguchi, and T. Tobe, "Characterization of 21 newly established esophageal cancer cell lines," Cancer, vol. 69, no. 2, pp. 277-284, 1992.
31. B. Li, S. W. Tsao, Y. Y. Li et al., "Id-1 promotes tumorigenicity and metastasis of human esophageal cancer cells through activation of PI3K/AKT signaling pathway," International Journal of Cancer, vol. 125, no. 11, pp. 2576-2585, 2009.
32. J. C. O. Tang, T. S. K. Wan, N. Wong et al., "Establishment and characterization of a new xenograft-derived human esophageal squamous cell carcinoma cell line SLMT-1 of Chinese origin," Cancer Genetics and Cytogenetics, vol. 124, no. 1, pp. 36-41, 2001.
33. E. Y. Tse, F. C. Ko, E. K. Tung et al., "Caveolin-1 overexpression is associated with hepatocellular carcinoma tumourigenesis and metastasis," Journal of Pathology, vol. 226, no. 4, pp. 645-653, 2012.
34. S.H.K. Chan, J.M. YeeKo, K.W. Chan et al., "The ECMprotein LTBP-2 is a suppressor of esophageal squamous cell carcinoma tumor formation but higher tumor expression associates with poor patient outcome," International Journal of Cancer, vol. 129, no. 3, pp. 565-573, 2011.
35. A.K. L. Cheung, J. C. Y. Ip, H. L. Lung, J. Z. Wu, S.W. Tsao, and M. L. Lung, "Polo-like kinase inhibitor Ro5203280 has potent antitumor activity in nasopharyngeal carcinoma," Molecular Cancer Therapeutics, vol. 12, no. 8, pp. 1393-1401, 2013.
36. Z. Huang, Y. Cheng, P.M. Chiu et al., "Tumor suppressor Alpha B-crystallin (CRYAB) associates with the cadherin/catenin adherens junction and impairs NPC progression-associated properties," Oncogene, vol. 31, no. 32, pp. 3709-3720, 2012.
37. A. K. L. Cheung, J. M. Y. Ko, H. L. Lung et al., "Cysteinerich intestinal protein 2 (CRIP2) acts as a repressor of NF- κB-mediated proangiogenic cytokine transcription to suppress tumorigenesis and angiogenesis," Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 20, pp. 8390-8395, 2011.
38. J. W. Chen, J. D. Xie, Y. H. Ling et al., "The prognostic effect of perineural invasion in esophageal squamous cell carcinoma," BMC Cancer, vol. 14, no. 1, article 313, 2014.
39. C. X. Bian, Z. Shi, Q. Meng, Y. Jiang, L. Z. Liu, and B. H. Jiang, "P70S6K 1 regulation of angiogenesis through VEGF and HIF-1alpha expression," Biochemical and Biophysical Research Communications, vol. 398, no. 3, pp. 395-399, 2010.
40. M. Cheung and J. R. Testa, "Diverse mechanisms of AKT pathway activation inhumanmalignancy," Current Cancer Drug Targets, vol. 13, no. 3, pp. 234-244, 2013.
41. S. Becker-Weimann, G. Xiong, S. Furuta et al., "NFkB disrupts tissue polarity in 3Dby preventing integration of microenvironmental signals," Oncotarget, vol. 4, no. 11, pp. 2010-2020, 2013.
42. A. Oksanen, P. Sipponen, R. Karttunen, and H. Rautelin, "Inflammation and intestinal metaplasia at the squamocolumnar junction in young patients with or without Helicobacter pylori infection," Gut, vol. 52, no. 2, pp. 194-198, 2003.
43. M. Quante, G. Bhagat, J. A. Abrams et al., "Bile acid and inflammation activate gastric cardia stem cells in a mouse model of barrett-like metaplasia," Cancer Cell, vol. 21, no. 1, pp. 36-51, 2012.
44. K. Y. Lam, S. Law, L. Tin, P. H. M. Tung, and J. Wong, "The clinicopathological significance of p21 and p53 expression in esophageal squamous cell carcinoma: an analysis of 153 patients," The American Journal of Gastroenterology, vol. 94, no. 8, pp. 2060-2068, 1999.
45. P.M. Treuting, S. M. Dintzis, C. W. Frevert, H. D. Liggitt, and K. S. Montine, Comparative Anatomy and Histology: A Mouse and Human Atlas, Elsevier, Amsterdam, The Netherlands, Academic Press, Boston, Mass, USA, 1st edition, 2012.
46. F. E. Sharkey and J. Fogh, "Metastasis of human tumors in athymic nude mice," International Journal of Cancer, vol. 24, no. 6, pp. 733-738, 1979.
47. J. Karar and A. Maity, "PI3K/AKT/mTOR pathway in angiogenesis," Frontiers in Molecular Neuroscience, vol. 4, article 51, 2011.
48. Y. Song, L. Li, Y. Ou et al., "Identification of genomic alterations inoesophageal squamous cell cancer," Nature, vol. 509, no. 7498, pp. 91-95, 2014.
49. Y. B. Gao, Z. L. Chen, J. G. Li et al., "Genetic landscape of esophageal squamous cell carcinoma," Nature Genetics, vol. 46, no. 10, pp. 1097-1102, 2014.
50. Z. A. Antonello and C. Nucera, "Orthotopic mouse models for the preclinical and translational study of targeted therapies againstmetastatic human thyroid carcinoma with BRAFV600E or wild-type BRAF," Oncogene, vol. 33, no. 47, pp. 5397-5404, 2013.